BACKGROUND: Cutaneous malignant melanoma (CMM) is one of the most common skin cancers worldwide. CMM pathogenesis involves genetic and environmental factors. Recent studies have led to the identification of new genes involved in CMM susceptibility: beyond CDKN2A and CDK4, BAP1, POT1, and MITF were recently identified as potential high-risk melanoma susceptibility genes. OBJECTIVE: This study is aimed to evaluate the genetic predisposition to CMM in patients from central Italy. METHODS: From 1998 to 2017, genetic testing was performed in 888 cases with multiple primary melanoma and/or familial melanoma. Genetic analyses included the sequencing CDKN2A, CDK4, BAP1, POT1, and MITF in 202 cases, and of only CDKN2A and CDK4 codon 24 in 686 patients. By the evaluation of the personal and familial history, patients were divided in two clinical categories: "low significance" and "high significance" cases. RESULTS: 128 patients (72% belonging to the "high significance" category, 28% belonging to the "low significance" category) were found to carry a DNA change defined as pathogenic, likely pathogenic, variant of unknown significance (VUS)-favoring pathogenic or VUS. CONCLUSIONS: It is important to verify the genetic predisposition in CMM patients for an early diagnosis of further melanomas and/or other tumors associated with the characterized genotype.
BACKGROUND:Cutaneous malignant melanoma (CMM) is one of the most common skin cancers worldwide. CMM pathogenesis involves genetic and environmental factors. Recent studies have led to the identification of new genes involved in CMM susceptibility: beyond CDKN2A and CDK4, BAP1, POT1, and MITF were recently identified as potential high-risk melanoma susceptibility genes. OBJECTIVE: This study is aimed to evaluate the genetic predisposition to CMM in patients from central Italy. METHODS: From 1998 to 2017, genetic testing was performed in 888 cases with multiple primary melanoma and/or familial melanoma. Genetic analyses included the sequencing CDKN2A, CDK4, BAP1, POT1, and MITF in 202 cases, and of only CDKN2A and CDK4 codon 24 in 686 patients. By the evaluation of the personal and familial history, patients were divided in two clinical categories: "low significance" and "high significance" cases. RESULTS: 128 patients (72% belonging to the "high significance" category, 28% belonging to the "low significance" category) were found to carry a DNA change defined as pathogenic, likely pathogenic, variant of unknown significance (VUS)-favoring pathogenic or VUS. CONCLUSIONS: It is important to verify the genetic predisposition in CMMpatients for an early diagnosis of further melanomas and/or other tumors associated with the characterized genotype.
Authors: Setareh Moghadasi; Diana M Eccles; Peter Devilee; Maaike P G Vreeswijk; Christi J van Asperen Journal: Hum Mutat Date: 2016-02-05 Impact factor: 4.878
Authors: I Bottillo; R La Starza; F C Radio; C Molica; L Pedace; T Pierini; C De Bernardo; L Stingeni; S Bargiacchi; A Paiardini; G Janson; C Mecucci; P Grammatico Journal: Clin Genet Date: 2017-11-10 Impact factor: 4.438
Authors: L Zuo; J Weger; Q Yang; A M Goldstein; M A Tucker; G J Walker; N Hayward; N C Dracopoli Journal: Nat Genet Date: 1996-01 Impact factor: 38.330
Authors: V Nikolaou; X Kang; A Stratigos; H Gogas; M C Latorre; M Gabree; M Plaka; C N Njauw; K Kypreou; I Mirmigi; I Stefanaki; H Tsao Journal: Br J Dermatol Date: 2011-11-02 Impact factor: 9.302
Authors: Sancy A Leachman; John Carucci; Wendy Kohlmann; Kimberly C Banks; Maryam M Asgari; Wilma Bergman; Giovanna Bianchi-Scarrà; Teresa Brentnall; Brigitte Bressac-de Paillerets; William Bruno; Clara Curiel-Lewandrowski; Femke A de Snoo; Tadeusz Debniak; Marie-France Demierre; David Elder; Alisa M Goldstein; Jane Grant-Kels; Allan C Halpern; Christian Ingvar; Richard F Kefford; Julie Lang; Rona M MacKie; Graham J Mann; Kurt Mueller; Julia Newton-Bishop; Håkan Olsson; Gloria M Petersen; Susana Puig; Darrell Rigel; Susan M Swetter; Margaret A Tucker; Emanuel Yakobson; John A Zitelli; Hensin Tsao Journal: J Am Acad Dermatol Date: 2009-10 Impact factor: 11.527
Authors: Sean V Tavtigian; Marc S Greenblatt; Steven M Harrison; Robert L Nussbaum; Snehit A Prabhu; Kenneth M Boucher; Leslie G Biesecker Journal: Genet Med Date: 2018-01-04 Impact factor: 8.822
Authors: Milena Casula; Antonio Muggiano; Antonio Cossu; Mario Budroni; Corrado Caracò; Paolo A Ascierto; Elena Pagani; Ignazio Stanganelli; Sergio Canzanella; Mariacristina Sini; Grazia Palomba; Giuseppe Palmieri Journal: BMC Cancer Date: 2009-10-03 Impact factor: 4.430
Authors: Oriol Calvete; Paula Martinez; Pablo Garcia-Pavia; Carlos Benitez-Buelga; Beatriz Paumard-Hernández; Victoria Fernandez; Fernando Dominguez; Clara Salas; Nuria Romero-Laorden; Jesus Garcia-Donas; Jaime Carrillo; Rosario Perona; Juan Carlos Triviño; Raquel Andrés; Juana María Cano; Bárbara Rivera; Luis Alonso-Pulpon; Fernando Setien; Manel Esteller; Sandra Rodriguez-Perales; Gaelle Bougeard; Tierry Frebourg; Miguel Urioste; Maria A Blasco; Javier Benítez Journal: Nat Commun Date: 2015-09-25 Impact factor: 17.694
Authors: W Bruno; B Dalmasso; M Barile; V Andreotti; L Elefanti; M Colombino; I Vanni; E Allavena; F Barbero; E Passoni; B Merelli; S Pellegrini; F Morgese; R Danesi; V Calò; V Bazan; A V D'Elia; C Molica; F Gensini; E Sala; V Uliana; P F Soma; M Genuardi; A Ballestrero; F Spagnolo; E Tanda; P Queirolo; M Mandalà; I Stanganelli; G Palmieri; C Menin; L Pastorino; P Ghiorzo Journal: ESMO Open Date: 2022-06-28